New stem cell approach could help more sickle cell patients

NCT ID NCT03121001

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase II trial is testing a stem cell transplant from a half-matched donor for people with severe sickle cell disease. Participants receive chemotherapy, radiation, and immune-suppressing drugs before the transplant to help the new cells take hold. The main goal is to see if the donor stem cells successfully engraft by day 60, which could lead to better disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant from a half-matched donor
What this could lead to: If successful, this approach could offer a way to control severe sickle cell disease using a donor who is only half-matched, making transplants available to more patients.
What could go wrong: This is an early phase II trial with only 50 participants, so results may not apply broadly. The transplant carries risks like graft failure, infection, and side effects from chemotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

University of Illinois at Chicago
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.